Financial Advocates Investment Management Reduces Stock Position in Haleon plc (NYSE:HLN)

Financial Advocates Investment Management cut its stake in Haleon plc (NYSE:HLN) by 21.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 16,187 shares of the company’s stock after selling 4,500 shares during the quarter. Financial Advocates Investment Management’s holdings in Haleon were worth $154,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in HLN. Atomi Financial Group Inc. grew its position in Haleon by 48.3% in the third quarter. Atomi Financial Group Inc. now owns 22,518 shares of the company’s stock worth $238,000 after acquiring an additional 7,330 shares during the period. CWM LLC grew its position in Haleon by 13.6% in the third quarter. CWM LLC now owns 24,978 shares of the company’s stock worth $264,000 after acquiring an additional 2,996 shares during the period. Ritholtz Wealth Management purchased a new position in Haleon in the third quarter worth approximately $275,000. Procyon Advisors LLC grew its position in Haleon by 1.7% in the third quarter. Procyon Advisors LLC now owns 162,911 shares of the company’s stock worth $1,724,000 after acquiring an additional 2,755 shares during the period. Finally, Creative Planning grew its position in Haleon by 15.2% in the third quarter. Creative Planning now owns 285,227 shares of the company’s stock worth $3,018,000 after acquiring an additional 37,566 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on HLN. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. Sanford C. Bernstein cut Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Stock Up 1.5 %

NYSE:HLN opened at $9.70 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The stock’s fifty day moving average is $9.53 and its two-hundred day moving average is $9.79. Haleon plc has a 52 week low of $7.89 and a 52 week high of $10.80. The stock has a market capitalization of $43.89 billion, a price-to-earnings ratio of 28.51, a price-to-earnings-growth ratio of 2.70 and a beta of 0.28.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.